Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Overview
This is an open label, 2-part early phase study designed to evaluate the safety, pharmacokinetics, radiation dosimetry, and preliminary efficacy of TLX090-Tx in patients with painful bone metastases.
Sponsor
Telix PharmaceuticalsPhase
Phase 1
Contacts
Jonathan Roger, MSc
jonathan.roger@telixpharma.com
579-366-1426 ext +1
ClinicalTrials.gov
NCT07197645Patient Education
Patient education not yet provided.
Publications
Publications not yet provided.
Locations
Loading…
Help us improve your experience